Home Blog Page 1266

Uluṟu’s Global Art Icon ‘Field of Light’ Marks 10 Years with Public Celebrations

Bruce Munro’s original installation reaches 750,000 visitors as new art, guest experiences and cultural collaborations are unveiled by Ayers Rock Resort, Uluṟu.

SYDNEY, Feb. 13, 2026 /PRNewswire/ — One of the world’s most recognisable large-scale light installations, Bruce Munro’s Field of Light, marks its 10th anniversary in 2026, celebrated with events and collaborations across Australia.

Opening in 2016 as a temporary installation, Field of Light has since welcomed more than 750,000 visitors and become Munro’s longest-running artwork. Set in the desert near Uluṟu, it spans the size of seven football fields and comprises 50,000 solar-powered stems inspired by native wildflowers after rain. The installation sits gently on Aṉangu Country, a place of continuing cultural significance stretching back tens of thousands of years.

Its influence now extends worldwide: Field of Light at Uluṟu helped inspire Munro installations at Sensorio in California, Longwood Gardens in Pennsylvania, Freedom Plaza in Manhattan and Salcombe in the UK. Yet Uluṟu remains the concept’s original and most enduring expression, drawing global audiences to Australia’s spiritual heart.

Ayers Rock Resort will mark the anniversary with a program of events, including a new mural in Melbourne on Wurundjeri Country, co-created by Aṉangu artist Valerie Brumby and Wurundjeri muralist Alex Kerr; VIP Evenings with Bruce Munro at Field of Light; complimentary Q&A sessions at the Resort; and refreshed menus for Field of Light dining experiences, featuring native and Indigenous ingredients from First Nations-owned Cooee Native Ingredients Australia.

Matt Cameron-Smith, CEO of Voyages Indigenous Tourism Australia, operator of Ayers Rock Resort, said: “It was meant to open for one year; it’s been ten. Field of Light is now one of the most loved and photographed experiences in Australia. We’re incredibly proud to see it reach a decade, shining brighter than ever. This anniversary is a chance to celebrate the artwork, the landscape and the cultural stories that make this place so special.”

Bruce Munro added: “Field of Light began as a personal response to the beauty and energy of the desert at Uluṟu. I never imagined it would grow into a global series of installations. Uluṟu is where the idea came to life and will always be the spiritual home of the artwork. Creating it was a dream come true, and it’s a personal joy to see it still shining in the landscape that inspired it.”

Aṉangu artist Valerie Brumby said: “Doing this artwork, painting the sunset over the Field of Light makes me feel happy and proud. This is good for the tourists to see, and we are making a mural to show everyone how beautiful it is.”

The anniversary year also highlights Ayers Rock Resort’s growing collection of immersive experiences: Wintjiri Wiṟu, a drone and light experience created in partnership with Aṉangu sharing a chapter of an ancient creation story, and Sunrise Journeys, a female-led laser and light experience co-created by three Aṉangu women artists.

For information/bookings, visit ayersrockresort.com.au

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

– Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value commercial partnerships in South Korea and Vietnam.

NEW TAIPEI CITY, Feb. 13, 2026 /PRNewswire/ — Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today issued a strategic corporate update. This review encapsulates a pivotal period characterized by the successful completion of the Phase II clinical trial for its lead candidate, MCS-8, and the concurrent attempt of its commercial footprint in key Asian markets. The Company believes the convergence of positive oncological endpoints with unexpected metabolic benefits potentially de-risks its pipeline and positions Jyong Biotech at the forefront of preventative medicine.

Unlocking the “Dual-Action” Potential of MCS-8: Oncology Meets Metabolic Health

The Company recently achieved an important milestone with the completion of its Phase II randomized, placebo-controlled trial for MCS-8, which enrolled over 700 high-risk subjects across 20 medical centers in Taiwan. As previously disclosed, the study’s primary efficacy analysis yielded a statistically significant 27.3% reduction in the overall incidence of prostate cancer in the MCS-8 arm compared to placebo. The data also demonstrated a 17.1% reduction in high-grade prostate cancer (Total Gleason Score ≥ 7). This finding is clinically profound, as high-grade malignancies represent the primary driver of prostate cancer mortality, and historical chemoprevention agents have often struggled to demonstrate safety or efficacy in this specific sub-population.

Further pathological stratification revealed a 35.2% reduction in the percentage of positive biopsy cores and a 24.4% reduction in the cancer-positive area within those cores. These metrics suggest that MCS-8 exerts a tangible biological effect on tumor burden and disease progression, potentially offering a superior alternative to the current standard of “active surveillance,” which carries the psychological burden of anxiety for patients waiting for disease progression.

Beyond its oncological efficacy, the Phase II data unveiled a significant secondary potential therapeutic profile regarding metabolic regulation. In results announced in January 2026, patients treated with MCS-8 for two years exhibited a statistically significant reduction in total cholesterol (P = 0.036). The study further highlighted a favorable lipid-modulating trend where the MCS-8 group showed decreased triglycerides (P = 0.05) and LDL levels (P = 0.018), alongside a significant increase in HDL (P = 0.003). In contrast, the placebo group experienced a statistically significant rise in fasting glucose (P = 0.022).

From a scientific perspective, the link between metabolic syndrome—characterized by dyslipidemia and hyperglycemia—and prostate carcinogenesis is well-documented in oncological literature. The ability of MCS-8 to simultaneously lower cancer incidence while improving the lipid profile suggests a potential synergistic mechanism of action that targets the metabolic dysregulation often fueling tumor growth. This “dual-action” capability supports the Company’s strategic evaluation of expanding MCS-8’s indications to include atherosclerosis and cardiovascular disease management.

Safety Profile and Cytoprotective Indicators

Long-term safety remains the primary barrier to entry for preventative therapies. The Phase II study provided significant indications of MCS-8’s safety profile over a two-year administration period. There were no serious adverse events related to the drug, and no negative impacts were observed on blood pressure, liver or kidney function.

Notably, the analysis of Lactate Dehydrogenase (LDH), a ubiquitous enzyme used as a clinical marker for tissue damage and cellular necrosis, offered further validation of safety. The placebo group exhibited a statistically significant increase in serum LDH levels (P = 0.024) over the trial period, potentially indicating baseline cellular stress or turnover inherent to the aging high-risk population. Conversely, the MCS-8 group showed no such elevation. The stability of LDH levels in the treatment arm serves as a biomarker for cytoprotection, reinforcing the hypothesis that MCS-8 does not induce cellular toxicity, a critical differentiator for a drug intended for long-term prophylactic use.

Embarking Commercialization via Non-Binding Strategic Asian Partnerships

Parallel to its clinical successes, Jyong Biotech has executed on its strategy to monetize its pipeline through regional co-commercialization. In late 2025, the Company formalized a non-binding Letter of Intent (LOI) with a premier South Korean pharmaceutical company to evaluate the in-licensing of MCS-2. As a recognized supplier to general hospitals and clinics, this partner offers the requisite infrastructure to navigate South Korea’s sophisticated regulatory landscape and reimbursement systems.

Subsequently, the Company expanded this initiative into Southeast Asia through a Memorandum of Understanding (MOU) with a specialized pharmaceutical distributor based in Ho Chi Minh City, Vietnam. This agreement initiates due diligence to define the regulatory and commercial pathway for MCS-2 in Vietnam, a market characterized by a rapidly aging population and increasing demand for urological therapeutics.

Management Commentary

“We believe that the past year has transformed Jyong Biotech from a development-stage entity into a company with clinically validated, multi-indication assets,” stated Fu-Feng Kuo, Chairwoman and CEO of Jyong Biotech. “The Phase II data for MCS-8 is particularly exciting because it addresses two of the most prevalent health concerns in the aging male population: prostate cancer risk and metabolic health. By demonstrating that we can potentially reduce cancer incidence while simultaneously improving lipid profiles, we have established a strong scientific foundation for our global Phase III trials in the future. Furthermore, our non-binding strategic alliances in Korea and Vietnam demonstrate our commitment to ensuring these innovative therapies reach patients efficiently. We are moving forward with a clear vision to redefine the standard of care in preventative urology.”

As of present day, MCS-2 and MCS-8 remain investigational new drug candidates and have not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.

About Jyong Biotech Ltd.

Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, pharmacology, toxicology, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization that is held in high esteem by the public.

For more information, please visit: https://www.jyongbio.com/, https://jyongir.com/.

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement, prospectuses, annual and interim reports, and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Jyong Biotech Ltd.
ir@jyongbio.com

Investor Relations
WFS Investor Relations Inc.
Email: services@wealthfsllc.com
Phone: +1 628 283 9214

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer

SAN FRANCISCO and SUZHOU, China, Feb. 13, 2026 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”,HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed in the pivotal Phase 3 clinical study (HeriCare-Breast01). The trial is evaluating the company’s developed IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate, HER2 ADC) as a first-line treatment for patients with unresectable locally advanced or metastatic HER2-positive breast cancer. IBI354 has two pivotal Phase 3 trials ongoing (HeriCare-Ovarian01, HeriCare-Breast01), which holds potential to deliver a new generation of ADC therapies characterized by “high potency and low-toxicity”.

HeriCare-Breast01 (NCT07377643) is a multicenter, randomized, open-label, active-controlled study designed to evaluate the safety and efficacy of IBI354, with or without pertuzumab, compared with the current standard-of-care, paclitaxel plus trastuzumab and pertuzumab (THP). The primary endpoint is progression-free survival (PFS).

Previously, in a multicenter Phase 1/2 study in participants with advanced solid tumors, a total of 88 participants with HER2-positive breast cancer were enrolled(the median prior treatment lines was 4) and were treated with 6-15 mg/kg doses of IBI354.

  • As of March 24, 2025, the overall confirmed objective response rate (cORR) was 59.1% and the disease control rate (DCR) was 90.9%.
  • Among them, ORR reached 72.4% and DCR reached 89.7% in 29 breast cancer participants treated with 9mg/kg Q3W.
  • The median follow-up time of 9mg/kg Q3W dose group was 13.6 months as of the cut-off date, and progression-free survival (PFS) was 14.1 month (95%CI: 8.3, NC). The data were presented at the ASCO 2025[Link].

IBI354 also demonstrated an excellent safety profile in this Phase 1/2 clinical study (n=368). 

  • No DLT was occurred up to 18mg/kg dose group.
  • The overall incidence of grade 3 or higher treatment-related adverse events (TRAEs) in 9mg/kg Q3W dose group was 21.0%, the incidence of TRAEs leading to dose interruption was 9.9%, the incidence of TRAEs leading to dose reduction was 1.2%, the overall incidence of TRAEs leading to discontinuation was 1.2%, and no TRAE leading to death reported.
  • The most common TRAEs are white blood cell count decreased, nausea and anemia. The incidence of interstitial lung disease was only 1.2%, all were grade 1.

The Principal Investigator of the HeriCare-Breast01 study, Binghe Xu, academician of the Chinese Academy of Engineering from Cancer Hospital Chinese Academy of Medical Sciences, stated, “We are pleased to complete the first patient enrollment for the HeriCare-Breast01 study at our center. Although first-line treatment for HER2-positive advanced breast cancer has improved substantially—with the THP regimen delivering durable responses for many patients—important clinical challenges remain. These include treatment discontinuation driven by toxicity and limited tolerability of currently available ADCs, particularly among older patients and those with comorbid conditions. As a next-generation HER2-targeted ADC, IBI354 has shown compelling antitumor activity in Phase 1/1b studies, achieving class-leading ORR and DCR, alongside a notably favorable safety profile. In particular, IBI354 has demonstrated reduced incidence of key adverse events such as interstitial lung disease (ILD), peripheral neuropathy, and neutropenia. This “high-efficacy, low-toxicity” therapeutic window may allow a broader range of patients to achieve sustained, high-quality treatment outcomes. We look forward to the Phase 3 HeriCare-Breast01 study to further validate this potential and advancing IBI354 toward becoming a new standard of care in the first-line treatment for HER2-positive advanced breast cancer. “

Dr. Zhou Hui, Chief R&D Officer (Oncology) of Innovent, stated, “The initiation of the pivotal Phase 3 HeriCare-Breast01 trial in China marks a significant milestone in the clinical translation of Innovent’s ADC pipeline. Leveraging the world’s leading antibody engineering and differentiated linker-payload technologies, Innovent has established a highly competitive and innovative TOPO1i ADC technology platform SoloTx®. IBI354 has demonstrated a compelling safety and efficacy profile in early-stage studies, strongly validating the strengths of our SoloTx® ADC platform. IBI354 holds strong potential to offer a new first-line treatment option for patients with HER2-positive advanced breast cancer—one that combines durable antitumor activity with favorable long-term tolerability. Looking ahead, Innovent will continue to advance innovation of next-generation IO+ADC, with a steadfast commitment to delivering improved therapeutic outcomes for cancer patients.”

About Breast Cancer

Breast cancer is one of the most common cancers among women worldwide. Approximately 1.3 million women are diagnosed with breast cancer each year, and about 30% of them develop locally advanced or metastatic breast cancer. The clinical proportion of HER2-positive breast cancer is approximately 20%[1]. Previous studies have demonstrated that overexpression of this HER2 gene plays a significant role in the occurrence and development of invasive breast cancer and is associated with an increased recurrence rate and poor prognosis [2]. At present, no ADC targeting HER2 has been fully approved for first-line treatment of advanced breast cancer in China. There is an urgent need for new drugs to improve the prognosis of patients.

About IBI354

IBI354 is an innovative HER2-targeted antibody–drug conjugate developed using Innovent’s proprietary SoloTx® ADC platform. Based on this platform, Innovent is promoting clinical trial studies multiple self-developed ADC molecules, which have shown promising safety and efficacy signals.

With a drug-to-antibody ratio (DAR) of 8, IBI354 delivers a high payload of effective drugs to tumors. The highly hydrophilic linker design contributes to its excellent biophysical and pharmacokinetic (PK) properties, while the hydrophobic payload enhances its bystander effect, targeting adjacent antigen-low or negative tumor cells. IBI354 exhibits extremely low exposure of free toxin in circulation and has an ideal safety profile based on pre-clinical and clinical studies. IBI354 has demonstrated remarkable anti-tumor activity in various tumor-bearing mice models, particularly in those resistant to HER2-targeted therapies and in metastatic tumors.

Starting from the urgent clinical needs, in addition to the Phase 3 studies (HeriCare-Breast01 and HeriCare-Ovarian01) already initiated in BC and PROC, Innovent will explore IBI354 in multiple solid tumor indications.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

1) Innovent does not recommend the use of any unapproved drug (s)/indication (s).

2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company.

Disclaimer: Innovent does not recommend any off-label usage.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Reference:

[1] Breast Cancer Expert Committee of Chinese Society of Clinical Oncology, Breast Cancer Professional Committee of China Anti-Cancer Association. Expert Consensus on Clinical Diagnosis and Treatment of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer (2021 version)[J]. National Medical Journal of China, 2021, 101(17): 1226-1231. DOI: 10.3760/cma.j.cn112137-20210318-00679.

[2] Tan M, Yu D. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol. 2007;608:119-129. doi:10.1007/978-0-387-74039-3_9.

 

Cboe Launches Nearly 24-Hour Trading in Russell 2000 Index Options

  • Cash-settled Russell 2000® Index (RUT) options now available during Cboe’s Global Trading Hours
  • Cboe now offers nearly 24×5 trading for RUT, S&P 500 Index and Cboe Volatility Index options
  • RUT options and Cboe’s Global Trading Hours both reached record volumes in 2025

CHICAGO, Feb. 13, 2026 /PRNewswire/ — Cboe Global Markets, Inc. (Cboe: CBOE), the world’s leading derivatives and securities exchange network, today announced Russell 2000 Index (RUT) and Russell 2000 Index Weeklys (RUTW) options are now available to trade on the Cboe Options Exchange nearly 24 hours a day, five days a week.

The addition of RUT options to Cboe’s Global Trading Hours (GTH) session offers European and Asia Pacific investors the ability to better manage U.S. small-cap exposure and trade during their local daytime hours. Cboe also offers S&P 500 Index (SPX), Mini-SPX (XSP) and Cboe Volatility Index (VIX) options during its GTH session, which experienced record volumes in 2025, up 27% compared to 2024.

RUT options saw record demand as investors increasingly turned to cash-settled, European-style options to help manage positioning and implement a broad range of trading strategies. Retail and institutional investors typically utilize RUT options to hedge or express market views, generate yield, or implement zero-days-to-expiry (0DTE) positions. In January, 0DTE trading represented 23% of total RUT options activity, reflecting growing investor demand for short-dated strategies.

“Cboe remains steadfast in our efforts to expand global access to U.S. markets and empower investors with the flexibility and tools they need to manage today’s market environment,” said Rob Hocking, Global Head of Derivatives at Cboe. “Demand for Russell 2000 Index options remained elevated as market participants navigated uncertainty, looked to diversify exposure and sought the utility index options can provide. By offering nearly 24-hour RUT trading alongside our SPX and VIX options, global investors can better act on their strategies in real time, regardless of time zone.”  

Milan Galik, Chief Executive Officer of Interactive Brokers, said: “Interactive Brokers is committed to expanding trading hours across the wide scope of asset classes we offer to our global clientele, as soon as and wherever such expansion is possible. With exchanges like Cboe now enabling 24/5 trading for Russell 2000 Index options, our clients worldwide gain the ability to manage their small-cap options positions around the clock and respond to international market developments in real-time.” 

Shawn Creighton, Director of Index Derivatives Solutions at FTSE Russell, said: “Cboe’s decision to introduce nearly 24-hour trading for Russell 2000 Index options is a significant milestone for global investors. As a key benchmark for U.S. small-cap equities, the expansion of Russell 2000 Index options will now offer investors enhanced flexibility to capture opportunities across time zones.”

On February 25 at 12:30 p.m. ET, Cboe will host a webinar featuring Mandy Xu, Head of Derivatives Market Intelligence at Cboe, and Catherine Yoshimoto, Director of Product Management at FTSE Russell. The discussion will cover the expansion of RUT trading hours, recent RUT options trading trends, and the outlook for small-cap performance and volatility. Visit here to sign up to receive webinar registration details and additional Cboe derivatives insights and analysis.

RUT and RUTW options now trade Monday through Friday during Cboe’s Regular Trading Hours (RTH) (9:30 a.m. ET to 4:15 p.m. ET), Global Trading Hours (GTH) (8:15 p.m. ET to 9:25 a.m. ET) and Curb Trading Hours (4:15 p.m. to 5:00 p.m. ET).

For more information on Cboe’s Global Trading Hours, visit Cboe Global Trading Hours.

About Cboe Global Markets
Cboe Global Markets (Cboe: CBOE), the world’s leading derivatives and securities exchange network, delivers cutting-edge trading, clearing, and investment solutions to people around the world. Cboe provides trading solutions and products in multiple asset classes, including equities, derivatives, and FX across North America, Europe, and Asia Pacific. Above all, we are committed to building a trusted, inclusive global marketplace that enables people to pursue a sustainable financial future. To learn more, visit www.cboe.com.

Cboe Media Contacts

Cboe Analyst Contact

Angela Tu

Tim Cave

Kenneth Hill, CFA

+1-646-856-8734

+44 (0) 7593-506-719

+1-312-786-7559

atu@cboe.com

tcave@cboe.com

khill@cboe.com

CBOE-OE

Cboe® and Cboe Global Markets® are registered trademarks or service marks of Cboe Exchange, Inc. All other trademarks and service marks are the property of their respective owners.

Options involve risk and are not suitable for all investors. Prior to buying or selling an option, a person must receive a copy of Characteristics and Risks of Standardized Options (ODD). Copies of the ODD are available from your broker or from The Options Clearing Corporation, 125 S. Franklin Street, Suite 1200, Chicago, IL 60606.

Cboe Global Markets, Inc. and its affiliates do not recommend or make any representation as to possible benefits from any securities, futures or investments, or third-party products or services. Cboe Global Markets, Inc. is not affiliated with S&P or the third-party sites referenced in this press release. Investors should undertake their own due diligence regarding their securities, futures, and investment practices. This press release speaks only as of this date. Cboe Global Markets, Inc. disclaims any duty to update the information herein.

Nothing in this announcement should be considered a solicitation to buy or an offer to sell any securities or futures in any jurisdiction where the offer or solicitation would be unlawful under the laws of such jurisdiction. Nothing contained in this communication constitutes tax, legal or investment advice or a recommendation to buy or sell a security, future, or other financial product. Investors must consult their tax adviser or legal counsel for advice and information concerning their particular situation.

Cboe Global Markets, Inc. and its affiliates make no warranty, expressed or implied, including, without limitation, any warranties as of merchantability, fitness for a particular purpose, accuracy, completeness or timeliness, the results to be obtained by recipients of the products and services described herein, or as to the ability of the indices referenced in this press release to track the performance of their respective securities, generally, or the performance of the indices referenced in this press release or any subset of their respective securities, and shall not in any way be liable for any inaccuracies, errors. Cboe Global Markets, Inc. and its affiliates have not calculated, composed or determined the constituents or weightings of the securities that comprise the third-party indices referenced in this press release and shall not in any way be liable for any inaccuracies or errors in any of the indices referenced in this press release.

There are important risks associated with transacting in any of the Cboe Company products discussed here. Before engaging in any transactions in those products, it is important for market participants to carefully review the disclosures and disclaimers contained at: https://www.cboe.com/us_disclaimers/. 

Cautionary Statements Regarding Forward-Looking Information

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. You can identify these statements by forward-looking words such as “may,” “might,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” and the negative of these terms and other comparable terminology. All statements that reflect our expectations, assumptions or projections about the future other than statements of historical fact are forward-looking statements. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from those expressed or implied by the forward-looking statements.

We operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Some factors that could cause actual results to differ include: the loss of our right to exclusively list and trade certain index options and futures products; economic, political and market conditions; compliance with legal and regulatory obligations; price and new products and services competition and consolidation in our industry; decreases in trading or clearing volumes, market data fees or a shift in the mix of products traded on our exchanges; legislative or regulatory changes or changes in tax regimes; our ability to protect our systems and communication networks from security vulnerabilities and breaches; our ability to attract and retain skilled management and other personnel; increasing competition by foreign and domestic entities; our business and operational dependence on and exposure to risk from third parties; factors that impact the quality and integrity of our and other applicable indices; our ability to manage our global operations, growth, and strategic acquisitions, wind downs, divestitures, or alliances effectively; increases in the cost of the products and services we use; our ability to operate our business without violating the intellectual property rights of others and the costs associated with protecting our intellectual property rights; our ability to minimize the risks, including our credit, liquidity, market, investment, counterparty, and default risks, associated with operating our  clearinghouses; our ability to accommodate trading and clearing volume and transaction traffic, including significant increases, without failure or degradation of performance of our systems; misconduct by those who use our markets or our products or for whom we clear transactions; challenges to our use of open source software code; our ability to meet our compliance obligations, including managing our business interests and our regulatory responsibilities; the loss of key customers or a significant reduction in trading or clearing volumes by key customers; damage to our reputation; the ability of our compliance and risk management methods to effectively monitor and manage our risks; restrictions imposed by our debt obligations and our ability to make payments on or refinance our debt obligations; our ability to maintain an investment grade credit rating; impairment of our goodwill, long-lived assets, investments or intangible assets; the accuracy of our estimates and expectations; and litigation risks and other liabilities. More detailed information about factors that may affect our actual results to differ may be found in our filings with the SEC, including in our Annual Report on Form 10-K for the year ended December 31, 2024 and other filings made from time to time with the SEC.

We do not undertake, and we expressly disclaim, any duty to update any forward-looking statement whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Titomic Enters Space Act Agreement with NASA

HUNTSVILLE, Ala., Feb. 13, 2026 /PRNewswire/ — Titomic Limited (ASX: TTT), a global leader in cold spray additive manufacturing utilizing their Titomic Kinetic Fusion™ technology, is pleased to announce the signing of a Space Act Agreement with NASA to conduct testing and evaluation of components produced using Titomic’s proprietary cold spray technology.

This is a significant opportunity for Titomic to demonstrate the capabilities of its advanced manufacturing processes in extreme environments. The initial evaluation by NASA will assess characteristics of Titomic-produced parts for potential use in aerospace applications. 

“We are honored to be working with NASA on the evaluation of our cold spray manufactured components,” said Jim Simpson, CEO and Managing Director at Titomic. “Our technology offers unique advantages in producing high-performance, lightweight parts without the need for heat or melting, making it ideally suited for space and aerospace applications where structural integrity and reliability are critical.”

“The successful completion of this initial testing phase could mark the potential for future collaboration in aerospace innovation and supply chain development,” said Dr. Patti Dare, Titomic USA President. 

This Space Act Agreement supports collaboration focused on technical assessment and information exchange and provides Titomic an opportunity to demonstrate the capabilities of its advanced manufacturing technologies for potential defense, space, and industrial applications.

This announcement has been authorized for release by Titomic’s Board of Directors.

Titomic Enters Space Act Agreement with NASA

HUNTSVILLE, Ala., Feb. 13, 2026 /PRNewswire/ — Titomic Limited (ASX: TTT), a global leader in cold spray additive manufacturing utilizing their Titomic Kinetic Fusion™ technology, is pleased to announce the signing of a Space Act Agreement with NASA to conduct testing and evaluation of components produced using Titomic’s proprietary cold spray technology.

This is a significant opportunity for Titomic to demonstrate the capabilities of its advanced manufacturing processes in extreme environments. The initial evaluation by NASA will assess characteristics of Titomic-produced parts for potential use in aerospace applications. 

“We are honored to be working with NASA on the evaluation of our cold spray manufactured components,” said Jim Simpson, CEO and Managing Director at Titomic. “Our technology offers unique advantages in producing high-performance, lightweight parts without the need for heat or melting, making it ideally suited for space and aerospace applications where structural integrity and reliability are critical.”

“The successful completion of this initial testing phase could mark the potential for future collaboration in aerospace innovation and supply chain development,” said Dr. Patti Dare, Titomic USA President. 

This Space Act Agreement supports collaboration focused on technical assessment and information exchange and provides Titomic an opportunity to demonstrate the capabilities of its advanced manufacturing technologies for potential defense, space, and industrial applications.

This announcement has been authorized for release by Titomic’s Board of Directors.

CGTN AMERICA & CCTV UN: CMG Presents “Prelude to the Spring Festival Gala” in New York City, Celebrating the Year of the Horse

WASHINGTON, Feb. 13, 2026 /PRNewswire/ — CGTN America & CCTV UN releases CMG Presents “Prelude to the Spring Festival Gala” in New York City, Celebrating the Year of the Horse

China Media Group presents the “Prelude to the Spring Festival Gala” in New York City, marking the joyous arrival of the Year of the Horse with an evening of cultural celebration, innovation, and global unity.

Now in its third consecutive year, the flagship “Prelude to the Spring Festival Gala”, which takes place on Friday, February 13th, in Midtown Manhattan, will welcome distinguished guests representing China, the U.S., and the United Nations, delivering heartfelt messages promoting cultural exchange, international cooperation, and global unity.

The Year of Horse begins on February 17. Watching the CMG Spring Festival Gala on the eve of the Chinese New Year has been a tradition for Chinese people. The celebration serves as a cultural symbol for the world to explore and understand China.

The “Prelude to the Spring Festival Gala” event in NYC will share that same spirit and will feature dynamic performances, showcasing both tradition and modernity. A Dragon Dance act will kick off the night, and later musicians and performers will appear on the stage singing and dancing to celebrate diversity and harmony.

Attendees will have the opportunity to enjoy a unique magic show by an artist known for large-scale illusions and immersive experiences. The show will include interaction with the audience and with talking robots.

There will be an outstanding AI works display from the “Bright Future of Humanity” global AI visual works call-for-submissions, which was launched last August, inviting young creators to use AI for positive, future-oriented storytelling.

One of the final acts will be a remarkable Tai Chi and martial arts demonstration, and the night will close with music and a fashion show featuring designs inspired by both tradition and technology.

The 2026 “Prelude to the Spring Festival Gala” will successfully reflect the spirit of cultural exchange and mutual respect, reinforcing the importance of shared traditions in a global community.

(This material is distributed by MediaLinks TV, LLC on behalf of CCTV. Additional information is available at the Department of Justice, Washington, D.C.)

Contact : Jose
Distribution@cgtnamerica.com

Opening of the Tuwaiq Sculpture 2026 Exhibition Marks Seventh Edition

RIYADH, Saudi Arabia, Feb. 13, 2026 /PRNewswire/ — The Royal Commission for Riyadh City, through the Riyadh Art Program, has announced the opening of the Tuwaiq Sculpture 2026 Exhibition, showcasing completed artworks from the 7th edition of the annual international Tuwaiq Sculpture Symposium. The exhibition will take place from February 9 to February 22, 2026, on Prince Mohammed bin Abdulaziz Street (Al Tahlia) in Riyadh and is open to the public free of charge.

Tuwaiq Sculpture 2026 presented by Riyadh Art, Royal Commission for Riyadh City.
Tuwaiq Sculpture 2026 presented by Riyadh Art, Royal Commission for Riyadh City.

Held under the theme Traces of What Will Be, this year’s edition explores transformation as both a material process and a condition shaped by the city’s evolution, reflecting Riyadh’s ongoing renewal. The Al Tahlia site holds historical significance as the location of Riyadh’s early water desalination stations, grounding the exhibition within a legacy of innovation, adaptation, and the pursuit of improved quality of life. This context provides a conceptual framework for the works on view.

The exhibition features 25 new large scale sculptures completed during the live sculpting phase, held from January 10 to February 5, 2026, allowing the public to witness the artistic process as it unfolded. Working with locally sourced stone and reclaimed metal, the artists transformed raw materials into finished works, emphasizing process, durability, and material intelligence within the public realm.

The 7th edition of the Tuwaiq Sculpture Symposium and Exhibition brings together Saudi and international artists from 18 countries, selected from more than 650 applications representing 50 countries worldwide through a specialized international jury. The participating artworks present diverse artistic interpretations of the symposium’s theme, addressing ideas of memory, responsible use of resources, environmental innovation, and the impact of human intervention within natural and urban contexts.

The curatorial framework for Tuwaiq Sculpture 2026 is overseen by Lulwa Alhomoud, Sarah Staton, and Rut Blees Luxemburg, whose combined expertise in public art, spatial practice, and contemporary visual culture has informed the development of works that engage closely with material, site, and future possibilities.

An interactive program accompanies the exhibition, including workshops, panel talks, and educational visits. This program reinforces the commitment of the Tuwaiq Sculpture Symposium to operate as an open cultural platform that encourages community participation and supports awareness of contemporary art.

All artworks produced during the Tuwaiq Sculpture 2026 edition will join the permanent Riyadh Art Collection and will be installed at prominent public locations across the city in the future, extending the program’s impact beyond the exhibition period and integrating contemporary sculpture into public spaces across Riyadh.

Since its launch in 2019, the Tuwaiq Sculpture Symposium has brought together more than 170 local and international artists, with each edition contributing new works to Riyadh Art’s Permanent Collection. To date, over 60 sculptures from past editions have been permanently installed across the city, with additional works scheduled for installation in future phases, reflecting the program’s long-term approach to expanding public art across Riyadh.

The Tuwaiq Sculpture 2026 Exhibition is open to the public free of charge from February 9 to February 22, 2026, on Prince Mohammed bin Abdulaziz Street (Al Tahlia) in Riyadh.

For more information, please visit: riyadhart.rcrc.gov.sa/en/tuwaiq-sculpture

Tuwaiq Sculpture 2026 presented by Riyadh Art, Royal Commission for Riyadh City.
Tuwaiq Sculpture 2026 presented by Riyadh Art, Royal Commission for Riyadh City.

 

Tuwaiq Sculpture 2026 presented by Riyadh Art, Royal Commission for Riyadh City.
Tuwaiq Sculpture 2026 presented by Riyadh Art, Royal Commission for Riyadh City.

 

Tuwaiq Sculpture 2026 presented by Riyadh Art, Royal Commission for Riyadh City.
Tuwaiq Sculpture 2026 presented by Riyadh Art, Royal Commission for Riyadh City.

 

Tuwaiq Sculpture 2026 presented by Riyadh Art, Royal Commission for Riyadh City.
Tuwaiq Sculpture 2026 presented by Riyadh Art, Royal Commission for Riyadh City.